Cost-effectiveness of second curettage for treatment of low-risk non-metastatic gestational trophoblastic neoplasia

摘要

Objective. Low-risk non-metastatic gestational trophoblastic neoplasia (GTN) has been treated with single agent chemotherapy, but second curettage is emerging as an alternative strategy with reported cure rates of 40%. We sought to estimate the cost-effectiveness of second curettage as the first line treatment of low-risk GTN.